[Federal Register Volume 74, Number 170 (Thursday, September 3, 2009)]
[Notices]
[Pages 45612-45613]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-21319]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Docket 36-2009]


Foreign-Trade Zone 170--Clark County, IN; Application for 
Subzone; Schwarz Pharma Manufacturing Ltd. (Pharmaceuticals 
Manufacturing), Seymour, IN

    An application has been submitted to the Foreign-Trade Zones Board 
(the Board) by the Ports of Indiana, grantee of FTZ 170, requesting 
special-purpose subzone status for pharmaceutical manufacturing 
facility of Schwarz Pharma Manufacturing Ltd. (Shwarz Pharma), located 
in Seymour, Indiana. The application was submitted pursuant to the 
provisions of the Foreign-Trade Zones Act, as amended (19 U.S.C. 81a-
81u), and the regulations of the Board (15 CFR part 400). It was 
formally filed on August 25, 2009.
    The Schwarz Pharma facility (450 employees, 28.8 acres, 1. 8 
billion

[[Page 45613]]

doses) is located at 1101 C Avenue West, Seymour, Indiana. The facility 
is used to manufacture, test, package and warehouse pharmaceutical 
products. Components and materials sourced from abroad (representing 
75% of the value of the finished product) include: alprostidil, edex 
applicators, lacosamide, moexipril, kremozin, vanlafaxim, and 
esomeprazole magnesium (duty rate ranges from duty free to 5.3%). The 
application also requests authority to include a broad range of inputs 
and finished pharmaceutical products that Schwarz Pharma may produce 
under FTZ procedures in the future. New major activity involving these 
inputs/products would require review by the FTZ Board.
    FTZ procedures could exempt Schwarz Pharma from customs duty 
payments on the foreign components used in export production. The 
company anticipates that less than 5 percent of the plant's shipments 
will be exported. On its domestic sales, Schwarz Pharma would be able 
to choose the duty rates during customs entry procedures that apply to 
Edex kits, Vimpat, Moexipril, Kremozin, Vanlafaxim and an acid reflux 
pharmaceutical (all duty free) for the foreign inputs noted above. FTZ 
designation would further allow Schwarz Pharma to realize logistical 
benefits through the use of weekly customs entry procedures. Customs 
duties also could possibly be deferred or reduced on foreign status 
production equipment. The request indicates that the savings from FTZ 
procedures would help improve the plant's international 
competitiveness.
    In accordance with the Board's regulations, Diane Finver of the FTZ 
Staff is designated examiner to evaluate and analyze the facts and 
information presented in the application and case record and to report 
findings and recommendations to the Board.
    Public comment is invited from interested parties. Submissions 
(original and 3 copies) shall be addressed to the Board's Executive 
Secretary at the address below. The closing period for their receipt is 
November 2, 2009. Rebuttal comments in response to material submitted 
during the foregoing period may be submitted during the subsequent 15-
day period to November 17, 2009.
    A copy of the application will be available for public inspection 
at the Office of the Executive Secretary, Foreign-Trade Zones Board, 
Room 2111, U.S. Department of Commerce, 1401 Constitution Avenue, NW., 
Washington, DC 20230-0002, and in the ``Reading Room'' section of the 
Board's Web site, which is accessible via http://www.trade.gov/ftz.
    For further information, contact Diane Finver at [email protected] or (202) 482-1367.

    Dated: August 26, 2009.
Andrew McGilvray,
Executive Secretary.
[FR Doc. E9-21319 Filed 9-2-09; 8:45 am]
BILLING CODE 3510-DS-P